Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride.

Aim: To compare the efficacy and safety of two analog insulins as starting regimens in insulin-naïve Type 2 diabetes patients.

Methods: In this randomized, open-label parallel study, twice-daily biphasic insulin aspart 30 (30% soluble and 70% protaminated insulin aspart; BIAsp 30) plus metformin (met) was compared with once-daily insulin glargine (glarg) plus glimepiride (glim) in 255 insulin-naïve patients (131 male; mean+/-SD age, 61.2+/-9.

[Therapeutic use of acetylsalicylic acid in diabetics].

Aterosclerosis is a leading cause of morbidity and mortality in diabetics. Macrovascular diseases--myocardial infarction, cerebral vascular accident, ischemic lower extremities--start in persons with diabetes earlier and in a bigger scope then in non-diabetics. Development of these changes is determined by diabetic vasculopathy which is connected with endothelial dysfunction, hypercoagulation state, and platelet abnormalities.

[The effect of walking exercise on aerobic capacity and serum lipids in type 2 diabetics].

Regular physical activity can have a favourable impact on other risk factors of ischaemic heart disease (IHD) and associated diabetes (DM), such as obesity, hypertension, dyslipidaemia, insulin resistance and others. This important part of treatment of diabetes is frequently difficult to implement because of the lack of willingness ("adherence") of type 2 diabetics to practice regular exercise, and unequivocal data are lacking on the intensity of exercise which will influence effectively these risk factors and be at the same time safe, readily available and psychologically acceptable. The objective of the work was to find out whether walking, i.

[Antihypertensives and their metabolic effects in diabetics].

Due to its frequent occurrence in diabetics, hypertension is a serious problem from the aspect of its effect on cardiovascular morbidity and mortality. Evaluation of metabolic and clinical effects of treatment of hypertension in diabetics should precede considerations on the selection of suitable antihypertensive treatment.